CD Patients on Originator Infliximab n=80 | CD Patients on Biosimilar Infliximab n=44 | P value | |
---|---|---|---|
Age at diagnosis Median ( range) | 13 years (8–16 ) | 12 years ( 3–16 ) | n.s |
Follow up period Median ( range) | 33 months (1-71) | 12 months (2–17 | <0.05 |
Patients on Azathioprine | 66/80 (83%) | 32/44 (73%) | n.s |
Patients with Anti-Infliximab antibodies | 56/80 (70%) | 34/44 (77%) | n.s |
Patients with dose/frequency escalation of Infliximab | 53/80 (66%) | 27/44 (62%) | n.s |
Patients in clinical remission | 46/80 (58%) | 27/44 (61%) | n.s |
Patients with major infusion reaction | 3/80 (4%) | 1/44 (2%) | n.s |